Immatics (IMTX) Shares Outstanding (Weighted Average) (2019 - 2025)
Immatics' (IMTX) quarterly Shares Outstanding (Weighted Average) came in at $1.5 billion in Q4 2025, up 993879351.98% year-on-year from N/an in Q4 2024, and up 104593833.35% quarter-over-quarter from $1421.6 in Q3 2025.
Immatics (IMTX) Shares Outstanding (Weighted Average) (2019 - 2025) Analysis & Trends
Immatics has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $1.5 billion for Q4 2025.
- Shares Outstanding (Weighted Average) for Q4 2025 came in at $1.5 billion, up 993879351.98% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 billion (up 993879351.98% YoY), and the FY2025 annual result was $1.4 billion, up 964651231.38% from the prior year.
- Shares Outstanding (Weighted Average) came in at $1.5 billion for Q4 2025 at Immatics, up from $1421.6 in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.5 billion in Q4 2025 to a low of $10.86 in Q1 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $70.3 million (2021), against an average of $269.6 million.
- Across the five-year window, Shares Outstanding (Weighted Average) plunged 100.0% in 2024 and surged 11294464339.2% in 2025, its largest moves.
- Immatics' Shares Outstanding (Weighted Average) stood at $72.0 million in 2021, then decreased by 4.71% to $68.6 million in 2022, then rose by 26.36% to $86.7 million in 2023, then slumped by 100.0% to $149.6 in 2024, then surged by 993879351.98% to $1.5 billion in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $1.5 billion (Q4 2025), $1421.6 (Q3 2025), and $1.3 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 1.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.49 Bn |
| Sep 30, 2025 | 1,421.57 |
| Jun 30, 2025 | 1.33 Bn |
| Mar 31, 2025 | 1.23 Bn |
| Dec 31, 2024 | 149.60 |
| Sep 30, 2024 | 43.93 |
| Jun 30, 2024 | 111.00 Mn |
| Mar 31, 2024 | 10.86 |
| Dec 31, 2023 | 86.66 Mn |
| Sep 30, 2023 | 90.77 Mn |
| Jun 30, 2023 | 631,576.15 |
| Mar 31, 2023 | 773.11 Mn |
| Dec 31, 2022 | 68.58 Mn |
| Sep 30, 2022 | 796.54 |
| Jun 30, 2022 | 1,195.10 |
| Mar 31, 2022 | 1,526.38 |
| Dec 31, 2021 | 71.97 Mn |
| Sep 30, 2021 | 74.19 Mn |
| Jun 30, 2021 | 939.33 |
| Mar 31, 2021 | 75.88 Mn |